Skip to main content
Clinical Trials/NCT05572489
NCT05572489
Recruiting
Not Applicable

Frequency of Cognitive Dysfunction in Individuals With Cervicogenic Headache

Konya Beyhekim Training and Research Hospital1 site in 1 country60 target enrollmentJanuary 1, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cervicogenic Headache
Sponsor
Konya Beyhekim Training and Research Hospital
Enrollment
60
Locations
1
Primary Endpoint
cognitive status
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The goal of this study was to determine the frequency of cognitive dysfunction in patients with cervicogenic headache.

participants will be asked questions to determine their cognitive status at once.

Detailed Description

A set of survey-type questions will be asked to the participants. Pain and fatigue levels of the patients were measured by visual pain scale (VAS), mood states by Beck depression scale (BDI) and Pain catastrophizing scale (Pain catastrophizing scale), quality of life by Short Form-36 (SF-36), and cognitive status by Standard Mini. mental test (SMMT) and Montreal cognitive assessment scale (MOCA).

Registry
clinicaltrials.gov
Start Date
January 1, 2022
End Date
January 1, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Konya Beyhekim Training and Research Hospital
Responsible Party
Principal Investigator
Principal Investigator

Savaş Karpuz

Medical doctor

Konya Beyhekim Training and Research Hospital

Eligibility Criteria

Inclusion Criteria

  • Clinical Diagnosis of cervicogenic headache be over 18

Exclusion Criteria

  • those under the age of 18 Those with neurological deficits Those with rheumatic diseases such as fibromyalgia, polymyalgia rheumatica, ankylosing spondylitis, rheumatoid arthritis Surgery in the cervical region in the past 6 months Those with widespread pain, significant pain in another anatomical location (eg, gonarthrosis) Those who use drugs or substances (alcohol, drugs, etc.) that may cause cognitive impairment Those with known neurological diseases such as cerebrovascular disease, MS, Parkinson's, dementia Those with major psychiatric illness Those with communication problems Those who have started psychiatric medical treatment in the last three months Those with significant hearing or vision problems Those with a history of uncontrollable systemic disease (cardiovascular, pulmonary, hepatic, renal, hematological, endocrine..)

Outcomes

Primary Outcomes

cognitive status

Time Frame: 01.12.2022

Study Sites (1)

Loading locations...

Similar Trials